Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I study of SOAz

S Nasca, D Jezekova, P Coninx

    Cancer Treatment Reports
    |December 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Chemical identification and quantification of volatile organic compounds emitted by sewage sludge.

    The Science of the total environment·2022
    Same author

    On the benefits of using multivariate analysis in mass spectrometric studies of combustion-generated aerosols.

    Faraday discussions·2019
    Same author

    Neuraxial block for delivery among women with low platelet counts: a retrospective analysis.

    International journal of obstetric anesthesia·2018
    Same author

    The contribution of comorbidities to mortality in hospitalized patients with heart failure.

    Clinical research in cardiology : official journal of the German Cardiac Society·2018
    Same author

    Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System.

    Journal of clinical pharmacy and therapeutics·2016
    Same author

    [Pharmacovigilance in Germany : It is about time].

    Der Internist·2016
    Same journal

    Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.

    Cancer treatment reports·1987
    Same journal

    IV melphalan in children.

    Cancer treatment reports·1987
    Same journal

    Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.

    Cancer treatment reports·1987
    Same journal

    Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

    Cancer treatment reports·1987
    Same journal

    Doxorubicin distribution in human breast cancer.

    Cancer treatment reports·1987
    Same journal

    Phase I study of echinomycin.

    Cancer treatment reports·1987
    See all related articles

    The phase I trial of SOAz, an inorganic cyclic derivative, found dose-limiting neutropenia and thrombocytopenia at doses >= 220 mg/M2. Cumulative toxicity is suspected due to long recovery times, with 220 mg/m2 every 6-8 weeks recommended for further study.

    Area of Science:

    • Oncology
    • Pharmacology
    • Toxicology

    Background:

    • SOAz is an inorganic cyclic derivative investigated for potential therapeutic applications.
    • Previous research or preclinical data on SOAz's efficacy and safety profile is limited.
    • Understanding the safety and tolerability of novel chemotherapeutic agents is crucial in cancer treatment.

    Purpose of the Study:

    • To evaluate the safety and tolerability of SOAz in a phase I clinical trial.
    • To determine the dose-limiting toxic effects (DLTs) of SOAz when administered as a single intravenous injection.
    • To identify a recommended dose for further clinical investigation.

    Main Methods:

    • A single intravenous (IV) injection of SOAz was administered to patients within one treatment cycle.

    Related Experiment Videos

  • Dose escalation was employed to identify the maximum tolerated dose (MTD).
  • Adverse events, particularly hematologic toxicity (neutropenia and thrombocytopenia), were closely monitored.

    • Main Results:

    • Dose-limiting toxicities, including neutropenia and thrombocytopenia, were observed at doses greater than or equal to 220 mg/M2, especially in patients with prior myelosuppressive treatment.
    • Prolonged time to nadir and recovery of blood cell counts suggested potential cumulative toxicity.
    • No other significant toxicities were reported, and no significant antitumor responses were observed in patients with measurable disease.

    Conclusions:

    • The recommended dose for further study of SOAz is 220 mg/m2 every 6-8 weeks, contingent upon hematologic recovery.
    • Careful monitoring for hematologic toxicities is essential in future trials.
    • Further investigation is warranted to explore SOAz's therapeutic potential and optimize its administration schedule.